DS
ONC

David Shaw’s BeOne Medicines Ltd ONC Stock Holding History

David Shaw’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,100
Closed -$638K – 5173
2025
Q4 		$638K Buy
2,100
+500
+31% +$164K ﹤0.01% 3803
2025
Q3 		$545K Hold
1,600
– – ﹤0.01% 3821
2025
Q2 		$387K Buy
+1,600
New +$392K ﹤0.01% 3754
2022
Q2 		– Sell
-6,200
Closed -$1.17M – 5853
2022
Q1 		$1.17M Hold
6,200
– – ﹤0.01% 3776
2021
Q4 		$1.68M Buy
+6,200
New +$2.09M ﹤0.01% 3512

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

David Shaw's ONC Position: Q3 2025 in Review

David Shaw sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 158,200 shares — an estimated $48M sold.

David Shaw first reported a position in ONC in Q1 2017 and held it in 10 quarters. The position peaked at $38.3M in Q2 2025. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • David Shaw reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • David Shaw sold 158,200 BeOne Medicines Ltd shares in Q3 2025, an estimated $48M.
  • David Shaw first reported a position in BeOne Medicines Ltd in Q1 2017 and held it in 10 quarters.
  • David Shaw's BeOne Medicines Ltd position peaked at $38.3M in Q2 2025.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.